Hints and tips:
...The New York-based pharma group has acquired four companies — Arena, ReViral, Biohaven and Global Blood Therapeutics — that it expects will contribute about $10bn in revenues in 2030....
...Biotech business Redx Pharma this week blamed low liquidity on London’s junior market for its decision to delist its shares from Aim and re-register as a private company....
Swiss pharma group acquires rights to develop and manufacture bowel disease treatment
...Merck’s research chief has called on the UK government to make the country more welcoming to pharma companies, ahead of the US-based drugmaker breaking ground on a £1bn research centre in London next week...
...Merger and acquisition activity, not research and development excellence, explains the persistence of top-ranking companies, according to Wharton professor Patricia Danzon....
...Regulators have taken notice after a study sparked fresh doubts over the usefulness of a Covid drug made by US pharma group Merck, raising questions about the costly procurement of antivirals during the...
...Prometheus was born in the early 2000s from research at Cedars-Sinai hospital in Los Angeles (Cedars-Sinai is a shareholder)....
...this Astellas incident on Japanese businesses is huge and there will be companies that will need to consider an exit from China due to concerns about their employee safety,” said Kenji Minemura, a senior research...
...Big pharma defends their patent strategies, arguing that intellectual property protection is required to justify continuing investment in existing drugs....
...truly) argued that the furious reaction from scientists and health professionals to the £1.1bn deal suggested — to quote one letter to the board — that it “could significantly hamper Vectura as a viable, research-orientated...
...Pharma companies are increasingly focusing their efforts on medicines that are expensive to develop and are targeted at smaller sets of people....
...“Investors haven’t really spent a lot of time understanding the breadth of our pipeline and our capabilities in research and development . . . now we’re beginning to showcase that over the next 18 months...
...And one deep dive: this online-only FT special report delves into the world of impact investing, with top pieces on faith and finance, how to pitch your social enterprise to investors, pharma funds, and...
...Over the past 15 years, PMI has poured $10.5bn into science and research into reduced-risk nicotine products, but in the early days he remembers struggling to even hire any staff....
...McLellan’s research on identifying and stabilising the structure of a protein that the RSV virus uses to infect human cells, published almost a decade ago, was instrumental in reviving Big Pharma’s interest...
...by Big Pharma’s focus on amyloid....
...Nevertheless, the so-called killer merger — a company taking out a rival solely to extinguish its threat — seems a lot rarer in tech than in industries such as pharma....
...“Generally speaking, if you are a pharmaceutical company, R&D [research and development] and regulatory engagement are in charge and everyone orbits around them....
...Sales of a third antiviral made by Japanese pharma company Shionogi are estimated at $0.5bn, down from $2.5bn, because of delays in the approval of the treatment....
...Telecommunications companies had a ratio of 55 to one, while it was 26 to one for the pharma, biotech and health sector....
...The US government recently signed a deal to procure approximately 1.7m courses of the drug at a cost of $1.2bn, and the pharma company also has agreements in place with several other countries....
...McDonnell said people who believed approval of the drug would lead to less investment into research for other Alzheimer’s treatments were “contradicted by precedent”, citing the history of research into...
...Merck has filed 129 patents linked to Keytruda, which could extend the period of exclusivity to 2036 and beyond, according to research by the Initiative for Medicines, Access & Knowledge, a non-profit group...
...The question gave the US pharma group a sense of urgency in the development of a coronavirus vaccine. Speed was crucial, so Pfizer had to change how it worked....
...It was unclear whether Yancopoulos had any particular knowledge of the details of Powell’s illness, including whether he did indeed receive an antibody treatment made by Regeneron or another pharma company...
International Edition